Karyopharm Therapeutics Inc. - Common Stock (KPTI)
8.9000
+0.0500 (0.56%)
NASDAQ· Last Trade: May 14th, 11:03 PM EDT
Detailed Quote
Previous Close
8.850
Open
9.520
Bid
8.510
Ask
9.970
Day's Range
8.700 - 10.23
52 Week Range
3.650 - 10.99
Volume
1,008,999
Market Cap
1.01B
PE Ratio (TTM)
-0.4969
EPS (TTM)
-17.9
Dividend & Yield
N/A (N/A)
1 Month Average Volume
396,761
Chart
About Karyopharm Therapeutics Inc. - Common Stock (KPTI)
Karyopharm Therapeutics is a biopharmaceutical company focused on developing novel therapies for the treatment of cancer and other serious diseases. The company is dedicated to discovering and commercializing innovative oral medications that target and disrupt the abnormal functioning of cellular pathways involved in disease progression. By leveraging its proprietary SINE (Selective Inhibitor of Nuclear Export) platform, Karyopharm aims to improve patient outcomes through the development of therapies that enhance treatment effectiveness while minimizing toxicity. Their research primarily concentrates on hematological cancers and solid tumors, with a commitment to advancing science and addressing significant unmet medical needs in oncology. Read More
Karyopharm Therapeutics (NASDAQ:KPTI) said it entered 2026 with several near-term clinical and regulatory catalysts, led by new Phase 3 data in myelofibrosis and an expected midyear readout in endometrial cancer, while reporting higher first-quarter revenue and reaffirming full-year guidance.
On th
Karyopharm (KPTI) Q3 2025 results show a revenue beat but an earnings miss. The stock rose pre-market as investors focus on XPOVIO sales growth and key Phase 3 data due in 2026.
